Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present GlaxoSmithKline plc (OTC: GLAXF).

Full DD Report for GLAXF

You must become a subscriber to view this report.


Recent News from (OTC: GLAXF)

Time To Pick 'Moaty' International Stocks
International stocks, whether it be in Europe or emerging markets, have had a rough 2018 so far. There is a sense that there must be some bargains out there, but many investors are not comfortable with those markets, and don't know how they can separate the wheat from the chaff . ...
Source: SeekingAlpha
Date: October, 19 2018 10:25
Arvinas IPO: 40% Is Cash, But Research Is At An Early Stage
With Yale University, Pfizer Inc. ( PFE ), Roche Ltd. ( RHHBY ) and Merck ( MRK ) collaborating with Arvinas Holding ( ARVN ) and shares at 2.5 its cash per share, the company seems a name that should retain the attention of investors. Having said that, Arvinas, which conducts research treatme...
Source: SeekingAlpha
Date: September, 25 2018 10:03
GSK's 2-Drug Combo For HIV Could Threaten Gilead
Gilead's ( GILD ) vaunted HCV franchise grew quarterly revenue by double digits in Q2 2018. HCV was less than 20% of total revenue, down from over 40% in the year earlier period. Its HIV franchise will likely drive the narrative from here. That could be problematic as GlaxoSmithKline ( GSK ), ...
Source: SeekingAlpha
Date: September, 17 2018 12:00
Liquidia IPO: Phase 3 Clinical Stage That Interested The Bill Gates Foundation
With remarkable investors like the foundation of Bill Gates, agreements with GlaxoSmithKline Plc ( GLAXF ) and a total addressable market of more than $4 billion, Liquidia Technologies, Inc. (LQDA) seems like a must-follow stock. Furthermore, Liquidia’s product candidate LIQ861 is at Ph...
Source: SeekingAlpha
Date: August, 08 2018 12:02
59 Top-Yield Healthcare Equities For June
Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a...
Source: SeekingAlpha
Date: June, 26 2018 05:02
50 Healthcare Top Yield Equities For April
Actionable Conclusions (1-10): Analysts Predicted 9.8% To 41.2% Net Gains For Top Ten Healthcare Equities By April 2019 Two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. ...
Source: SeekingAlpha
Date: April, 10 2018 09:58
Healthcare Top Gainers: Sanofi, Merck, Glaxo, Patterson, And AstraZeneca By Broker February Targets
Actionable Conclusions (1-10): Analysts Predicted 4.22% To 26.43% Net Gains For Top Ten Healthcare Equities By February 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (...
Source: SeekingAlpha
Date: March, 01 2018 14:28
Healthcare Net Gain Leaders: Getinge, Glaxo, Sanofi, Merck And Medical Facilities By Broker January Target Reckoning
Actionable Conclusions (1-10): Analysts Predicted 3.18% To 23.18% Net Gains For Top Ten Healthcare Dogs By January 2019 Seven of ten top dividend-yielding Healthcare dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. ...
Source: SeekingAlpha
Date: January, 28 2018 01:20
Healthcare Net Gains Leaders For 2018 Are Glaxo, Sanofi, Merck, Owens, Novartis, And Pfizer Per Broker Targets
Actionable Conclusions (1-10): Analysts Predicted 3.18% To 23.18% Net Gains For Top Ten Healthcare Dogs By December 2018 Six of ten top dividend-yielding Healthcare dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They ...
Source: SeekingAlpha
Date: December, 29 2017 01:26
Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In
Actionable Conclusions (1-10): Analysts Predicted 6.8% To 32.2% Net Gains For Ten Healthcare Dogs By November 2018 Four of ten top dividend-yielding Healthcare dogs were verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (They are t...
Source: SeekingAlpha
Date: November, 14 2017 14:02

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1418.3418.8318.8318.34503
2018-12-1318.6018.84318.9918.501,085
2018-12-1218.3118.5018.5018.316,375
2018-12-1118.5518.3518.5518.35766
2018-12-1018.49518.2018.49518.2016,805

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-147250314.3141Cover
2018-12-12296,3750.4549Cover
2018-12-071,7901,81098.8950Short
2018-12-06104621.7391Cover
2018-12-041,0722,70639.6157Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GLAXF.


About GlaxoSmithKline plc (OTC: GLAXF)

Logo for GlaxoSmithKline plc (OTC: GLAXF)

Not available

 

Contact Information

 

 

Current Management

  • JeanPierre Garnier / CEO
  • John Coombe / CFO
  • Simon Bicknell / Secretary

Current Share Structure

     


    Recent Filings from (OTC: GLAXF)

    Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
    Filing Type: 25-NSEFiling Source: edgar
    Filing Date: May, 17 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 15 2018
    Registration of certain classes of securities 12(b) of the Securities Exchange Act
    Filing Type: 8-A12BFiling Source: edgar
    Filing Date: May, 15 2018
    Registration of certain classes of securities 12(b) of the Securities Exchange Act
    Filing Type: 8-A12BFiling Source: edgar
    Filing Date: May, 15 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 15 2018
    Prospectus filed under Rule 424(b)(2)
    Filing Type: 424B2Filing Source: edgar
    Filing Date: May, 14 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 11 2018
    Free Writing Prospectus
    Filing Type: FWPFiling Source: edgar
    Filing Date: May, 11 2018
    Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
    Filing Type: 6-KFiling Source: edgar
    Filing Date: May, 11 2018
    Prospectus filed under Rule 424(b)(2)
    Filing Type: 424B2Filing Source: edgar
    Filing Date: May, 10 2018

     

     


    Daily Technical Chart for (OTC: GLAXF)

    Daily Technical Chart for (OTC: GLAXF)


    Stay tuned for daily updates and more on (OTC: GLAXF)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: GLAXF)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GLAXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GLAXF and does not buy, sell, or trade any shares of GLAXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/